Scarica l'app Stockscreener
2.32
4.04%
0.09
Dopo l'orario di chiusura:
2.32
Precedente Chiudi:
$2.23
Aprire:
$2.18
Volume 24 ore:
59,364
Relative Volume:
0.35
Capitalizzazione di mercato:
$12.38M
Reddito:
-
Utile/perdita netta:
$-23.92M
Rapporto P/E:
-0.0921
EPS:
-25.1834
Flusso di cassa netto:
$-22.74M
1 W Prestazione:
-4.53%
1M Prestazione:
-2.52%
6M Prestazione:
-81.44%
1 anno Prestazione:
-90.34%
Intervallo 1D:
$2.18
$2.33
Intervallo di 1 settimana:
$2.18
$2.44
Portata 52W:
$1.79
$28.61
Moleculin Biotech Inc Stock (MBRX) Company Profile
Nome
Moleculin Biotech Inc
Settore
Industria
Telefono
713-300-5160
Indirizzo
5300 MEMORIAL DRIVE, HOUSTON, TX
Compare MBRX vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
2.32 | 12.38M | 0 | -23.92M | -22.74M | -25.18 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-09 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-12 | Downgrade | Maxim Group | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Moleculin Biotech Inc Borsa (MBRX) Ultime notizie
MBRX Stock Price, Quote & Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Tangible book value per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Advancing Cancer Therapies Amid Clinical Milestones and Biotech Volatility - AD HOC NEWS
MBRX Stock Chart | MOLECULIN BIOTECH INC (NASDAQ:MBRX) - ChartMill
Meme Stocks: What are Moleculin Biotech Incs earnings expectations2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Moleculin Biotech files to sell 6.37M shares of common stock for holders - MSN
Total debt per share of Moleculin Biotech, Inc. – LSE:0K2H - TradingView
Moleculin Biotech Stock: Clinical-Stage Biotech Focused on Oncology Innovations for North American I - AD HOC NEWS
Moleculin Biotech (NASDAQ: MBRX) registers 6.37M resale shares tied to warrants - Stock Titan
Scalable Biotech Manufacturing Unlocks a $14B Market - Benzinga
Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Sell Signal: Is Moleculin Biotech Inc undervalued by DCF analysis2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Moleculin at Roth Conference: Annamycin’s Market Potential By Investing.com - Investing.com Canada
Moleculin at Roth Conference: Annamycin’s Market Potential - Investing.com
MBRX: Annamycin's phase III AML trial nears key data, highlighting strong efficacy and zero cardiotoxicity - TradingView
MBRX: Annamycin's phase III AML trial nears key data, highlighting its efficacy and safety advantages - TradingView
MBRX: HC Wainwright & Co. Reiterates Buy Rating and Price Target - GuruFocus
Moleculin enrolls 45th patient in pivotal AML trial By Investing.com - Investing.com Canada
Moleculin Biotech Reports 40% Remission Rate in Early Phase 3 AML Study for Annamycin, Accelerating Toward 90 Patient Enrollment 12 - Minichart
Moleculin Biotech (MBRX) Advances Phase 2B/3 Trial for Acute Mye - GuruFocus
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout - Bitget
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout - tipranks.com
Moleculin enrolls 45th patient in pivotal AML trial - investing.com
Moleculin Biotech, Inc. Prepares for Key Interim Results in Pivotal AML Trial with 40% Early Remission Rate - Quiver Quantitative
Moleculin Hits 45-Subject Milestone, Sets Mid-2026 MIRACLE Interim Readout - TradingView
Moleculin (NASDAQ: MBRX) hits 45-subject milestone in pivotal MIRACLE AML trial - Stock Titan
If You Invested $1,000 in Moleculin Biotec (MBRX) - Stock Titan
MBRX SEC FilingsMoleculin Biotec 10-K, 10-Q, 8-K Forms - Stock Titan
Moleculin Biotech, Inc.: Fundamental Analysis and Financial Ratings | MOL0 | US60855D4088 - marketscreener.com
MBRX Expects Cash Reserves to Fund Operations Through Q3 2026 - GuruFocus
Optimism Surrounds Moleculin's (MBRX) MIRACLE Trial Progress - GuruFocus
Moleculin Biotech Updates Investors with New Corporate Presentation - tipranks.com
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026 - The Manila Times
Moleculin Biotech Reports 40% Preliminary CRc Rate in First 30 Patients of MIRACLE Trial for Relapsed/Refractory AML - Quiver Quantitative
[8-K] Moleculin Biotech, Inc. Reports Material Event - Stock Titan
Moleculin Biotech reports FY2025 net loss $33.6M, cash $8.9M; MIRACLE interim CRc 40% - TradingView
Moleculin's leukemia drug heads for a 45-patient readout in 2026 - Stock Titan
Moleculin (Nasdaq: MBRX) details 2025 loss and MIRACLE AML trial progress - Stock Titan
Moleculin Biotech 2025 Annual Report: Annamycin Clinical Trials & Pipeline Update - Minichart
Moleculin Biotech 10-K: No Revenue, Net Loss $33.6M, Ops Loss $25.1M - TradingView
Moleculin Biotech (NASDAQ: MBRX) outlines Annamycin Phase 3 AML strategy - Stock Titan
Moleculin Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Moleculin to Present at 38th Annual ROTH Conference - The Manila Times
Moleculin Biotech Inc expected to post a loss of $6.11 a shareEarnings Preview - TradingView
Net current asset value per share of Moleculin Biotech, Inc. – FWB:MOL0 - TradingView
Moleculin Reports Second Quarter 2024 Financial Results and Prov - GuruFocus
MBRX Should I Buy - Intellectia AI
Moleculin Biotech releases CEO update on leukemia trial By Investing.com - Investing.com India
Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study - The Manila Times
Moleculin Biotech releases CEO update on leukemia trial - Investing.com
Moleculin Biotech (MBRX) seeks vote on 6.37M warrants and name change - Stock Titan
Moleculin Biotech Inc Azioni (MBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):